…
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Enanta Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapeutics, primarily for antiviral, respiratory and liver diseases. Long-term growth drivers include progression of its clinical-stage candidates, a chemistry-driven discovery platform and potential partnerships; positive clinical readouts or licensing could materially de-risk programs and support value realization. Investors may find the company attractive for its targeted pipeline and platform-based discovery approach.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Income before tax | -83.55M | -117.79M | -131.00M | -122.19M | -107.58M |
| Net income | -81.89M | -116.05M | -133.82M | -121.75M | -79.00M |
| Selling general administrative | 43.93M | 57.85M | 52.89M | 45.48M | 32.54M |
| Gross profit | 60.74M | 67.64M | 79.20M | 86.16M | 97.07M |
| Reconciled depreciation | 4.59M | 2.34M | 2.37M | 2.97M | 3.33M |
| Ebit | -75.87M | -106.85M | -125.85M | -123.84M | -112.91M |
| Ebitda | -70.78M | -104.51M | -123.48M | -120.95M | -109.57M |
| Depreciation and amortization | 5.09M | 2.34M | 2.37M | 2.89M | 3.33M |
| Non operating income net other | - | - | - | 0.08M | -0.03M |
| Operating income | -85.35M | -121.69M | -137.21M | -123.84M | -109.57M |
| Other operating expenses | 150.67M | 189.33M | 216.41M | 210.00M | 206.65M |
| Interest expense | 7.68M | 10.94M | 5.15M | 1.57M | 5.33M |
| Tax provision | -1.66M | -1.74M | 2.82M | -0.43M | -28.58M |
| Interest income | 9.44M | 14.77M | 11.36M | 1.57M | 2.02M |
| Net interest income | 1.76M | 3.83M | 6.21M | 1.57M | 2.02M |
| Income tax expense | -1.66M | -1.74M | 2.82M | -0.43M | -28.58M |
| Total revenue | 65.32M | 67.64M | 79.20M | 86.16M | 97.07M |
| Total operating expenses | 146.09M | 189.33M | 216.41M | 210.00M | 206.65M |
| Cost of revenue | 4.59M | - | - | - | - |
| Total other income expense net | 1.80M | 3.90M | 6.21M | 1.66M | 1.99M |
| Net income from continuing ops | -81.89M | -116.05M | -133.82M | -121.75M | -79.00M |
| Net income applicable to common shares | - | - | - | -121.75M | -79.00M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total assets | 280.73M | 376.65M | 462.27M | 375.41M | 438.79M |
| Other current assets | 8.59M | 13.02M | 13.26M | 13.45M | 51.44M |
| Total liab | 216.01M | 247.84M | 245.54M | 54.08M | 39.36M |
| Total stockholder equity | 64.72M | 128.81M | 216.74M | 321.33M | 399.43M |
| Other current liab | 12.75M | 13.55M | 35.08M | 20.94M | 22.43M |
| Common stock | 0.21M | 0.21M | 0.21M | 0.21M | 0.20M |
| Capital stock | 0.21M | 0.21M | 0.21M | 0.21M | 0.20M |
| Retained earnings | -404.93M | -323.04M | -207.00M | -73.18M | 48.58M |
| Other liab | - | - | - | 0.45M | 0.56M |
| Other assets | - | - | - | 4.66M | 0.70M |
| Cash | 32.30M | 37.23M | 85.39M | 43.99M | 57.21M |
| Total current liabilities | 48.55M | 57.53M | 62.79M | 29.83M | 36.17M |
| Current deferred revenue | - | - | 18.34M | - | - |
| Net debt | 168.76M | 188.82M | -58.88M | -18.73M | -51.88M |
| Short term debt | 33.86M | 35.99M | 5.28M | 2.89M | 4.20M |
| Short long term debt total | 201.06M | 226.06M | 26.51M | 25.26M | 5.33M |
| Other stockholder equity | 469.77M | 451.34M | 423.27M | 396.61M | 349.53M |
| Property plant equipment | - | - | - | 29.75M | 10.65M |
| Total current assets | 204.34M | 299.85M | 422.79M | 311.71M | 319.02M |
| Long term investments | - | - | 0.00M | 29.29M | 108.42M |
| Net tangible assets | - | - | - | 321.33M | 399.43M |
| Short term investments | 156.57M | 210.95M | 284.52M | 205.24M | 186.80M |
| Net receivables | 6.88M | 38.65M | 39.62M | 49.04M | 60.83M |
| Inventory | - | - | - | - | -37.26M |
| Accounts payable | 1.95M | 8.00M | 4.10M | 6.00M | 9.54M |
| Accumulated other comprehensive income | -0.34M | 0.30M | -1.17M | -3.72M | -0.38M |
| Common stock total equity | - | - | - | 0.21M | 0.20M |
| Retained earnings total equity | - | - | - | -73.18M | 48.58M |
| Non currrent assets other | 0.09M | 0.09M | 4.77M | 4.66M | 0.70M |
| Non current assets total | 76.40M | 76.80M | 39.48M | 63.70M | 119.77M |
| Capital lease obligations | 57.90M | 55.47M | 26.51M | 25.26M | 5.33M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Investments | 40.35M | 58.23M | -53.58M | 57.02M | 37.74M |
| Change to liabilities | - | - | - | -4.63M | 3.77M |
| Total cashflows from investing activities | 40.35M | 58.23M | - | 54.90M | 36.99M |
| Net borrowings | - | -27.48M | - | - | - |
| Total cash from financing activities | -26.62M | -27.63M | 198.13M | 20.03M | 3.08M |
| Change to operating activities | - | - | - | -0.37M | 6.84M |
| Net income | -81.89M | -116.05M | -133.82M | -121.75M | -79.00M |
| Change in cash | -5.54M | -48.16M | 41.39M | -9.85M | -29.93M |
| Begin period cash flow | 41.20M | 89.36M | 47.96M | 57.81M | 87.74M |
| End period cash flow | 35.66M | 41.20M | 89.36M | 47.96M | 57.81M |
| Total cash from operating activities | -19.27M | -78.76M | -103.15M | -84.78M | -70.00M |
| Depreciation | 5.09M | 2.34M | 2.37M | 2.97M | 3.33M |
| Change to account receivables | 31.76M | 0.97M | 11.70M | 3.26M | -0.08M |
| Sale purchase of stock | - | - | - | 21.26M | 3.61M |
| Other cashflows from financing activities | -0.28M | -0.29M | 198.13M | -1.23M | 3.08M |
| Change to netincome | - | - | - | 27.21M | 19.35M |
| Capital expenditures | 12.90M | 17.95M | 9.06M | 2.12M | 0.75M |
| Change receivables | - | - | - | 3.26M | -0.08M |
| Cash flows other operating | - | - | - | 9.66M | -25.21M |
| Cash and cash equivalents changes | - | - | - | -9.85M | -29.93M |
| Change in working capital | 39.91M | 7.13M | 8.02M | 6.79M | -13.69M |
| Stock based compensation | 18.57M | 26.80M | 28.22M | 26.97M | 20.99M |
| Other non cash items | -0.95M | 1.02M | 2.60M | 0.24M | -1.98M |
| Free cash flow | -32.17M | -96.71M | -112.21M | -86.91M | -70.75M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals Inc |
-0.36 4.51% |
7.62 | - | 44.05 | 5.49 | 3.78 | 3.80 | 41.13 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Jay R. Luly | Pres, CEO & Director | 1956 |
| Mr. Paul J. Mellett Jr. | Sr. VP of Fin. & Admin. and CFO | 1955 |
| Dr. Yat Sun Or Ph.D. | Sr. VP of R&D and Chief Scientific Officer | 1952 |
| Ms. Tara Lynn Kieffer Ph.D. | Sr. VP of New Product Strategy & Devel. | 1978 |
| Mr. Brendan Luu | Sr. VP of Bus. Devel. | NA |
| Ms. Jennifer Viera | Sr. Director of Investor Relations & Corp. Communications | NA |
| Mr. Nathaniel S. Gardiner J.D. | Sr. VP, Gen. Counsel & Sec. | 1954 |
| Dr. Nathalie Adda M.D. | Consultant | 1966 |
| Dr. Scott T. Rottinghaus | Sr. VP & Chief Medical Officer | NA |
| Dr. Jay R. Luly Ph.D. | President, CEO & Director | 1956 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.